GSK’s Second Flu Vaccine Would Boost Capacity To 30 Mil. Doses
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK submits a BLA for FluLaval, acquired as part of its 2005 purchase of ID Biomedical, to FDA March 23.
You may also be interested in...
GSK’s FluLaval Approval Raises Estimated Influenza Vaccine Doses To 115 Mil.
FluLaval is approved by FDA for immunization of adults against influenza Oct. 5.
GSK’s FluLaval Approval Raises Estimated Influenza Vaccine Doses To 115 Mil.
FluLaval is approved by FDA for immunization of adults against influenza Oct. 5.
GSK To File H5N1 Pandemic Flu Vaccine In Europe By Year-End
Trial using novel ASO3 adjuvant shows high immune response at low dose of antigen.